SEARCH

SEARCH BY CITATION

References

  • 1
    Marotti G, Zallone AZ. Changes in the vascular network during the formation of Haversian systems. Acta Anat (Basel). 1980; 106(1): 84100.
  • 2
    Maes C, Kobayashi T, Selig MK, Torrekens S, Roth SI, Mackem S, Carmeliet G, Kronenberg HM. Osteoblast precursors, but not mature osteoblasts, move into developing and fractured bones along with invading blood vessels. Dev Cell. 2010; 19(2): 32944.
  • 3
    Zelzer E, McLean W, Ng YS, Fukai N, Reginato AM, Lovejoy S, D'Amore PA, Olsen BR. Skeletal defects in VEGF(120/120) mice reveal multiple roles for VEGF in skeletogenesis. Development. 2002; 129(8): 189304.
  • 4
    Qing H, Pajevic PD, Barry K, Dusevich V, Wysolmerski JJ, Bonewald L. PTHR1 in osteocytes plays a major role in perilacunar remodeling through the activation of “osteoclastic” genes in osteocytes. J Bone Miner Res. 2010; 25 (Suppl 1). Available at http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=fbaf7531-7536ce7534-7543fc-a7854-7593cb42413eaf.
  • 5
    Qin L, Mak AT, Cheng CW, Hung LK, Chan KM. Histomorphological study on pattern of fluid movement in cortical bone in goats. Anat Rec. 1999; 255(4): 3807.
  • 6
    Bianco P. Bone and the hematopoietic niche: a tale of two stem cells. Blood. 2011; 117(20): 52818.
  • 7
    Eash KJ, Greenbaum AM, Gopalan PK, Link DC. CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow. J Clin Invest. 2010; 120(7): 242331.
  • 8
    Napoli C, William-Ignarro S, Byrns R, Balestrieri ML, Crimi E, Farzati B, Mancini FP, de Nigris F, Matarazzo A, D'Amora M, Abbondanza C, Fiorito C, Giovane A, Florio A, Varricchio E, Palagiano A, Minucci PB, Tecce MF, Giordano A, Pavan A, Ignarro LJ. Therapeutic targeting of the stem cell niche in experimental hindlimb ischemia. Nat Clin Pract Cardiovasc Med. 2008; 5(9): 5719.
  • 9
    Wang Y, Wan C, Deng L, Liu X, Cao X, Gilbert SR, Bouxsein ML, Faugere MC, Guldberg RE, Gerstenfeld LC, Haase VH, Johnson RS, Schipani E, Clemens TL. The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest. 2007; 117(6): 161626.
  • 10
    Wan C, Gilbert SR, Wang Y, Cao X, Shen X, Ramaswamy G, Jacobsen KA, Alaql ZS, Eberhardt AW, Gerstenfeld LC, Einhorn TA, Deng L, Clemens TL. Activation of the hypoxia-inducible factor-1alpha pathway accelerates bone regeneration. Proc Natl Acad Sci USA. 2008; 105(2): 68691.
  • 11
    Kaigler D, Wang Z, Horger K, Mooney DJ, Krebsbach PH. VEGF scaffolds enhance angiogenesis and bone regeneration in irradiated osseous defects. J Bone Miner Res. 2006; 21(5): 73544.
  • 12
    Prisby R, Guignandon A, Vanden-Bossche A, Mac-Way F, Linossier MT, Thomas M, Laroche N, Malaval L, Langer M, Peter ZA, Peyrin F, Vico L, Lafage-Proust MH. Intermittent PTH 1-84 is osteoanabolic but not osteoangiogenic and relocates bone marrow blood vessels closer to bone forming sites. J Bone Miner Res. 2011; 26: 25832596.
  • 13
    Grunewald FS, Prota AE, Giese A, Ballmer-Hofer K. Structure–function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling. Biochim Biophys Acta. 2010; 1804(3): 56780.
  • 14
    Demer L, Tintut Y. The bone–vascular axis in chronic kidney disease. Curr Opin Nephrol Hypertens. 2010; 19(4): 34953.
  • 15
    London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004; 15(7): 194351.
  • 16
    Wahl O, Oswald M, Tretzel L, Herres E, Arend J, Efferth T. Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products. Curr Med Chem. 2011; 18(21): 313655.
  • 17
    Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002; 302(3): 105561.
  • 18
    Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003; 349(13): 120715.
  • 19
    Sim FH, Kelly PJ. Relationship of bone remodeling, oxygen consumption, and blood flow in bone. J Bone Joint Surg Am. 1970; 52(7): 137789.
  • 20
    Weinstein RS, Wan C, Liu Q, Wang Y, Almeida M, O'Brien CA, Thostenson J, Roberson PK, Boskey AL, Clemens TL, Manolagas SC. Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice. Aging Cell. 2010; 9(2): 14761.
  • 21
    Wang DS, Miura M, Demura H, Sato K. Anabolic effects of 1,25-dihydroxyvitamin D3 on osteoblasts are enhanced by vascular endothelial growth factor produced by osteoblasts and by growth factors produced by endothelial cells. Endocrinology. 1997; 138(7): 295362.
  • 22
    Stahl A, Wenger A, Weber H, Stark GB, Augustin HG, Finkenzeller G. Bi-directional cell contact-dependent regulation of gene expression between endothelial cells and osteoblasts in a three-dimensional spheroidal coculture model. Biochem Biophys Res Commun. 2004; 322(2): 68492.
  • 23
    Bouletreau PJ, Warren SM, Spector JA, Peled ZM, Gerrets RP, Greenwald JA, Longaker MT. Hypoxia and VEGF up-regulate BMP-2 mRNA and protein expression in microvascular endothelial cells: implications for fracture healing. Plast Reconstr Surg. 2002; 109(7): 238497.
  • 24
    Wohl GR, Towler DA, Silva MJ. Stress fracture healing: fatigue loading of the rat ulna induces upregulation in expression of osteogenic and angiogenic genes that mimic the intramembranous portion of fracture repair. Bone. 2009; 44(2): 32030.
  • 25
    Cheng SL, Shao JS, Cai J, Sierra OL, Towler DA. Msx2 exerts bone anabolism via canonical Wnt signaling. J Biol Chem. 2008; 283(29): 2050522.
  • 26
    Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, Suda T, Matsuo K. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab. 2006; 4(2): 11121.
  • 27
    Korff T, Dandekar G, Pfaff D, Fuller T, Goettsch W, Morawietz H, Schaffner F, Augustin HG. Endothelial ephrinB2 is controlled by microenvironmental determinants and associates context-dependently with CD31. Arterioscler Thromb Vasc Biol. 2006; 26(3): 46874.
  • 28
    Bochenek ML, Dickinson S, Astin JW, Adams RH, Nobes CD. Ephrin-B2 regulates endothelial cell morphology and motility independently of Eph-receptor binding. J Cell Sci. 2010; 123(Pt 8): 123546.
  • 29
    Maes C, Goossens S, Bartunkova S, Drogat B, Coenegrachts L, Stockmans I, Moermans K, Nyabi O, Haigh K, Naessens M, Haenebalcke L, Tuckermann JP, Tjwa M, Carmeliet P, Mandic V, David JP, Behrens A, Nagy A, Carmeliet G, Haigh JJ. Increased skeletal VEGF enhances beta-catenin activity and results in excessively ossified bones. EMBO J. 2010; 29(2): 42441.
  • 30
    Jilka RL, O'Brien CA, Bartell SM, Weinstein RS, Manolagas SC. Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms. J Bone Miner Res. 2010; 25(11): 242737.
  • 31
    Ohishi M, Chiusaroli R, Ominsky M, Asuncion F, Thomas C, Khatri R, Kostenuik P, Schipani E. Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor. Am J Pathol. 2009; 174(6): 216071.
  • 32
    Cackowski FC, Anderson JL, Patrene KD, Choksi RJ, Shapiro SD, Windle JJ, Blair HC, Roodman GD. Osteoclasts are important for bone angiogenesis. Blood. 2010; 115(1): 1409.
  • 33
    Meng XW, Liang XG, Birchman R, Wu DD, Dempster DW, Lindsay R, Shen V. Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats. J Bone Miner Res. 1996; 11(4): 4219.
  • 34
    Narita Y. [Effect of intermittent administration of human PTH on experimental osteopenia in adult rat: a histomorphometric study of both trabecular and cortical bone of the vertebrae]. Nihon Seikeigeka Gakkai Zasshi. 1995; 69(10): 102736.
  • 35
    Huang MS, Lu J, Ivanov Y, Sage AP, Tseng W, Demer LL, Tintut Y. Hyperlipidemia impairs osteoanabolic effects of PTH. J Bone Miner Res. 2008; 23(10): 16729.
  • 36
    Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res. 2001; 16(10): 184653.
  • 37
    Cheng SL, Shao JS, Halstead LR, Distelhorst K, Sierra O, Towler DA. Activation of vascular smooth muscle parathyroid hormone receptor inhibits Wnt/beta-catenin signaling and aortic fibrosis in diabetic arteriosclerosis. Circ Res. 2010; 107(2): 27182.
  • 38
    Sutliff RL, Weber CS, Qian J, Miller ML, Clemens TL, Paul RJ. Vasorelaxant properties of parathyroid hormone-related protein in the mouse: evidence for endothelium involvement independent of nitric oxide formation. Endocrinology. 1999; 140(5): 207783.
  • 39
    Abdallah Y, Ross G, Dolf A, Heinemann MP, Schluter KD. N-terminal parathyroid hormone-related peptide hyperpolarizes endothelial cells and causes a reduction of the coronary resistance of the rat heart via endothelial hyperpolarization. Peptides. 2006; 27(11): 292734.
  • 40
    Bakre MM, Zhu Y, Yin H, Burton DW, Terkeltaub R, Deftos LJ, Varner JA. Parathyroid hormone-related peptide is a naturally occurring, protein kinase A-dependent angiogenesis inhibitor. Nat Med. 2002; 8(9): 9951003.
  • 41
    Jamal SA, Hodsman AB. Reducing the risk of re-fracture in the dialysis population: is it time to consider therapy with PTH analogues?. Semin Dial. 2011; 24(1): 125.